Comparing SG&A Expenses: Pharming Group N.V. vs TG Therapeutics, Inc. Trends and Insights

Biotech SG&A Expenses: A Decade of Strategic Shifts

__timestampPharming Group N.V.TG Therapeutics, Inc.
Wednesday, January 1, 2014404202524518692
Thursday, January 1, 2015527955719886580
Friday, January 1, 2016807391312631689
Sunday, January 1, 20174486407321977998
Monday, January 1, 20185348890420759000
Tuesday, January 1, 20196589636120838000
Wednesday, January 1, 202069968267121812000
Friday, January 1, 202192047281152137000
Saturday, January 1, 202213181900083231000
Sunday, January 1, 202387501000122706000
Loading chart...

Infusing magic into the data realm

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Pharming Group N.V. and TG Therapeutics, Inc. from 2014 to 2023. Over this period, Pharming Group N.V. saw a significant increase in SG&A expenses, peaking in 2022 with a 1,318% rise from 2014. Meanwhile, TG Therapeutics, Inc. experienced a more volatile trend, with a notable spike in 2021, where expenses surged by 522% compared to 2014. This fluctuation highlights the dynamic nature of the biotech industry, where strategic investments in administration and sales can drive growth. As these companies navigate the complexities of the market, understanding their financial strategies offers valuable insights into their operational priorities and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025